Acurx Pharmaceuticals, Inc.
ACXP · XNASCIK 1736243fmd_1P4V67WJMYQS5P17HY707GSJKWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 2 | 2 | 5 | 6 | 5 | 2 |
| Selling, general and administrative | – | 0 | – | – | – | – |
| Total operating expenses | 5 | 13 | 12 | 15 | 14 | 8 |
| Operating income | – | – | – | – | (14) | (8) |
| Interest and investment income | – | – | – | – | 0 | 0 |
| Income tax expense | 0 | – | 0 | – | – | – |
| Net income | (5) | (13) | (12) | (15) | (14) | (8) |